The FDA granted fast track designation to EO-3021 for the treatment of advanced or metastatic gastric and gastroesophageal ...

During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...

Efficacy findings from the phase 2 AGAVE-201 support the use of axatilimab, which was approved by the FDA for recurrent or ...

Sun Gwe Ahn, MD, discusses an exploratory analysis of the HERA trial at the 2024 ESMO Congress. An exploratory analysis of the HERceptin Adjuvant (HERA; NCT00045032) trial investigated the benefits of ...

During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...

During a Case-Based Roundtable® event, Virginia F. Borges, MD, MMSc, discussed treatment selection for a patient with ER+, ...

NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.

Anil Parwani, MD, PhD, discusses the challenges and opportunities he has encountered in either implementing or utilizing ...

During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented ...